A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy

Trial Profile

A Two-Part Study to Assess the Safety and Tolerability, Pharmacokinetics, and Effects on Histology and Different Clinical Parameters of Givinostat in Ambulant Children With Duchenne Muscular Dystrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Dec 2017

At a glance

  • Drugs Givinostat (Primary)
  • Indications Duchenne muscular dystrophy
  • Focus Therapeutic Use
  • Sponsors Italfarmaco
  • Most Recent Events

    • 04 Dec 2017 Status changed from active, no longer recruiting to completed.
    • 23 Feb 2016 Planned End Date changed from 1 Aug 2015 to 1 Aug 2017, as reported by ClinicalTrials.gov.
    • 02 Dec 2014 Planned primary completion date changed from 1 Nov 2014 to 1 Dec 2014 according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top